首页 | 本学科首页   官方微博 | 高级检索  
检索        

人血管内皮生长因子与绿色荧光蛋白标记双基因共表达AAV载体的构建及鉴定
引用本文:黄向辉,时志斌,王坤正,党晓谦,杨佩,余鹏博.人血管内皮生长因子与绿色荧光蛋白标记双基因共表达AAV载体的构建及鉴定[J].中国组织工程研究与临床康复,2008,12(29):5755-5758.
作者姓名:黄向辉  时志斌  王坤正  党晓谦  杨佩  余鹏博
基金项目:国家自然科学基金(30600624) the National Natural Science Foundation of China
摘    要:背景:血管内皮生长因子能促进内皮细胞分裂增殖及血运重建,诱导血管生成,近年来以血管内皮生长因子为基础的基因治疗已逐步试用于临床.但质粒载体转染率低、腺病毒载体对机体的免疫原性及存在潜在感染危险等问题尚需探讨.目的:拟构建带有绿色荧光蛋白标记并携带hVEGF165基因的无致病性重组腺相关病毒,鉴定并测定病毒滴度及活性.设计、时间和地点:开放性实验,于2007-03/09在陕西省疾病预防控制中心病毒室完成.材料:病毒包装细胞AAV-293、病毒滴度检测细胞AAV-HT1080购自Stratagene公司;Ecoli DH5.菌株由陕西省疾病预防控制中心保存:AAV helper-free system腺相关病毒包装系统中pAAV-IRES-hrGFP质粒包含绿色荧光报告基因,购自Stratagene公司;重组携带hVEGF165基因的质粒pUC18-hVEGF165由西安交通大学第二医院骨科时志斌博士构建.方法: 从含有hVEGF165基因的pUC18-hVEGF165质粒中扩增出hVEGF165片段,插入腺相关病毒骨架质粒pAAV-IRES-hrGFP,构建重组骨架质粒pAAV-hVEGF165-IRES-hrGFP.将此重组质粒和腺相关病毒包装质粒pAAV-RC、辅助质粒pAAV-Helper磷酸钙法共转染AAV-293细胞,通过同源重组产生重组腺相关病毒rAAV-hVEGF165-GFP.荧光显微镜下监测病毒包装效率,裂解AAV_293细胞收获重组病毒并进行浓缩纯化.应用该重组病毒感染AAV-HT1080细胞,荧光计数法测定病毒滴度,并通过病毒基因组外源基因hVEGF165扩增鉴定重组病毒的包装是否成功.应用该重组病毒感染AAV-HT1080细胞.主要观察指标:荧光显微镜下监测病毒包装效率.荧光计数法测定病毒滴度,并通过病毒基因组外源基因hVEGF165扩增鉴定重组病毒的包装是否成功.结果:扩增产物经DNA测序确定为hVEGF165 cDNA片段,重组骨架质粒pAAV-hVEGF165-IRES-hrGFP经双酶切鉴定正确.病毒包装效率达95%以上,收获纯化病毒滴度达5.5×1011vg/mL.提取重组病毒基因组成功扩增出外源目的基因片段hVEGF165,证实重组病毒rAAV-VEGF165-GFP包装成功.结论:成功构建带有绿色荧光蛋白标记并携带hVEGF165基因的无致病性重组腺相关病毒rAAV-VEGF165-GFP.收获的病毒具有较高滴度和感染活性.

关 键 词:血管内皮生长因子  腺相关病毒  绿色荧光蛋白

Construction and identification of recombinant adeno- associated virus vector co-expressing human vascular endothelial growth factor and green fluorescent protein
Abstract:BACKGROUND: Vascular endothelial growth factor (VEGF) can specifically promote the division and proliferation of endothelial cells and the revascularization, finally induce angiopoiesis. Recently, VEGF-based gene therapy has been gradually used in clinical trials, but some limits on usually used vectors deserve further studies, including the low transfection efficiency of plasmid vector, the immunogenicity of adnovirus vector to host cells and the potential risk of infection. OBJECTIVE: To construct the non-pathogenic recombinant adeno-associated vires (AAV) co-expressing human vascular endethelial growth factor 165 (hVEGF165) and green fluorescent protein (GFP) label and measure the virus titer and assess its biological activity.DESIGN, TIME AND SETTING: The open experiment was performed at the Vitrus Laboratory of Shanxi Provincial Center for Disease Control and Prevention from March to September 2007.MATERIALS: AAV-293 virus packaging cell line, AAV HT-1080 cells were purchased from Swatagene, USA. E.coli DH5α was a stocked strain from Shanxi Provincial Center for Disease Control and Prevention. AAV Helper Free System (pAAV-IRES-GFP vector containing GFP label) was purchased from Stratagene, USA. Plasmid pUC18-hVEGF165 was constructed previously by Dr.Shi from Department of Orthopaedics of Second Affiliated Hospital of Xi'an Jiaotong University.METHODS: The hVEGF165 gone from plasmid pUC18-hVEGF165 was amplified and inserted into plasmid pAAV-IRES-hrGFP. Then recombinant plasmid pAAV-hVEGF165-IRES-hrGFP, pAAV-RC and pAAV-Helper were co-transfected into AAV-293 cells to complete rAAV-hVEGF165-IRES-hrGFP packaging through homologous recombination. The efficiency of A.AV packaging was monitored under a fluorescent microscope, and the recombinant viral particles were harvested from infected AAV-293 cells and further concentrated and purified. The recombinant virus infected the AAV-HT1080 cells, the virus titer was measured by fluorescence counting, and the recombinant AAV-hVEGF165-IRES-hrGFP was verified by the amplification of the exogenous gene of hVEGF165 from virus genome.MAIN OUTCOME MEASURES: Virus packaging efficiency was monitored under the fluorescence microscope. Virus filer was measured by fluorescent counting. The packaging of recombinant virus was determined by the amplification of the exogenous hVEGF165 gene.RESULTS: The amplified products were verified as hVEGF165 gene by DNA sequencing, and the recombinant pAAV-hVEGF165-IRES-hrGFP was confirmed by double digestion. The system provided a high packaging ratio of over 95% and the purified recombinant virus had a high titer of 5.5×1011 vp/mL. The recombinant virus was confirmed by exogenous human VEGF165 gene from virus genome.CONCLUSION: The non-pathogenic rAAV-hVEGF165-GFP simultaneously carrying hVEGF165 and GFP 1abel is successfully constructed, with a high titer and satisfying biological activity.
Keywords:
本文献已被 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号